ArticleMethodsX2026
A comprehensive electrooculography measurement system and protocols for screening myasthenia gravis.
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a neuromuscular disorder that can precipitate serious and fatal complications, especially when respiratory muscles are affected. Current electrodiagnostic methods, such as Single Fiber Electromyography (SFEMG) and Repetitive Nerve Stimulation (RNS), have notable limitations. While SFEMG is sensitive to neuromuscular abnormalities rather than being specific for MG, it is also a semi-invasive procedure that requires supervision by specialist clinicians and an expensive clinical setup. Conversely, RNS is highly specific for MG, but its sensitivity decreases in cases of low severity. Prior studies, including our previous work, have demonstrated that the manifestation of MG in affecting eye movements can be indirectly quantified using electrooculography (EOG) signals. This non-invasive method could develop into a widely used and easily deployed screening method, especially for early detection of MG using readily obtainable biomarkers. With this goal in mind, our research team developed data collection protocols using a standardized eye movement protocol that could be implemented in a standard clinical setting to acquire EOG data. In this article, we present the experimental setup, test protocols, sample outcomes, and preliminary analysis approaches. Common artifacts encountered, as well as technical and logistical challenges associated with such a setup, are also discussed.1.An approach to non-invasively detect and quantify MG using eye movement signals.2.Data collection protocols for acquiring eye movement signals designed for MG quantification3.Novel eye movement-based biomarkers in quantifying MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.